Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir
| Autor: | Sasisopin Kiertiburanakul, Jintanat Ananworanich, Ploenchan Chetchotisakd, Phitsanu Raksakulkarn, Wisit Prasithsirikul, Sasiwimol Ubolyam, Bernard Hirschel, Somboon Tansuphasawadikul, Kiat Ruxrungtham, Warangkana Munsakul, Wendy Snowden, Malte Schutz, Sunee Sirivichayakul, Thidarat Jupimai |
|---|---|
| Přispěvatelé: | Other departments |
| Jazyk: | angličtina |
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male Reverse Transcriptase Inhibitors/therapeutic use Genotype Drug Resistance Viral/ genetics HIV Infections Drug resistance Viral genetics HIV Protease Saquinavir/ therapeutic use Antiretroviral Therapy Highly Active Drug Resistance Viral Antiretroviral naive medicine Humans Pharmacology (medical) Protease inhibitor (pharmacology) Treatment Failure Saquinavir HIV-1/enzymology/ genetics HIV Protease Inhibitors/ therapeutic use ddc:616 Pharmacology Ritonavir HIV Infections/ drug therapy/enzymology/virology business.industry Ritonavir/ therapeutic use HIV Protease/ genetics/metabolism HIV Protease Inhibitors Viral Load Thailand Virology Antiretroviral therapy HIV Reverse Transcriptase Infectious Diseases HIV Reverse Transcriptase/antagonists & inhibitors/ genetics/metabolism Mutation HIV-1 Reverse Transcriptase Inhibitors Female business Viral load medicine.drug |
| Zdroj: | Antiviral therapy, 11(5), 631-635. International Medical Press Ltd Antiviral Therapy, Vol. 11, No 5 (2006) pp. 631-635 |
| ISSN: | 1359-6535 |
| Popis: | BackgroundThere are few data on the selection of resistance by ritonavir-boosted saquinavir (SQV/r), particularly in antiretroviral (ARV)-naive patients.ObjectiveTo assess the incidence of virological failure and evolution of resistance in ARV-naive individuals receiving SQV/r in the induction phase of the Staccato trial.MethodsARV-naive subjects ( n=272) received SQV/r 1,600/100 mg once daily with two nucleoside reverse transcriptase inhibitors (NRTIs) for at least 24 weeks. Patients were defined as having virological failure (VF) when there were two consecutive HIV-1 RNA measurements >500 copies/ml after week 12. Viral genotypes (reverse transcriptase [RT] and protease [PRO]) were determined at baseline in all patients and as close as possible to the time of initial failure in patients experiencing VF.ResultsVF was observed in 9/272 patients receiving SQV/r 1,600/100 mg once daily with two NRTIs (3.3%) and occurred 19–48 weeks after treatment initiation. Eight of these patients were evaluable at failure. No major PRO mutations were detected, but 2/8 displayed single new minor PRO substitutions (M36I, L10I) at VF that were known or suspected not to have been present at baseline; both these substitutions exist as natural polymorphisms. A third patient displayed a single new RT mutation (M184I).ConclusionsSQV/r plus two NRTIs (1,600/100 mg once daily) is an effective initial treatment option for ARV-naive patients, resulting in a low rate of viral rebound (3.3%). Furthermore, no major protease mutations were detected following VF, suggesting that future treatment options are preserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|